Building on the most widely leveraged standardized reference in TMF management today, with version 2.0 used by more than a hundred life science sponsors, CROs and technology vendors, the next major release of the TMF Reference Model will incorporate feedback from its extensive industry use to enhance content clarity and add a XML-based mechanism for simplifying the interchange of electronic TMF content between organizations.
The V3.0 development team is currently composed of nearly 100 experts, and more volunteer participation is always welcome. To get involved, please visit http://tmfrefmodel.com/join-the-tmf-reference-model-project-team/join-here/ . We welcome your participation, insight and feedback.
What is the TMF Reference Model?
The TMF Reference Model provides a single, unified interpretation of regulations and TMF practices that has been vetted across the industry. Since its origination in 2009, the TMF Reference Model is managed by a group of Drug Information Association volunteers, comprised of over 350 contributors from more than 200 life science organizations and is a non-profit, vendor-agnostic initiative. The TMF Reference Model presents a consensus position in accordance with industry opinion regarding the standard content of a Trial Master File, to include identifying all the content that individually and collectively permit the evaluation of the conduct of a trial and the quality of the data produced.
The TMF Reference Model allows for standardization of contents, structure, naming and metadata. The most obvious benefit of standardization is increased efficiency of gathering, managing, and analyzing trial content, but additional benefits of standardization include increased inspection surety and reduced variability when collaborating with business partners. As it does not prescribe any specific structure, nor define the processes required to create or manage TMFs, it can be adapted to any electronic or paper TMF and does not endorse, nor require, any specific technology for application.
The TMF Reference Model is a valuable tool for:
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.